Current nanotechnological approaches for an effective delivery of bioactive drug molecules to overcome drug resistance tuberculosis

Current Pharmaceutical Design

Volumn 21, Issue 22, 2015, Pages 3076-3089

  Garg, Tarun ^a   Rath, Goutam ^a   Murthy, Rayasa R ^a   Gupta, Umesh D ^b   Vatsala, Palakkod G ^c   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^c INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Colloidal systems; Drug delivery; Drug resistance; Drug targeting; Patient compliance; Tuberculosis

Indexed keywords

CYCLODEXTRIN; DENDRIMER; ISCOM; LIPOSOME; NIOSOME; POLYMER; SOLID LIPID NANOPARTICLE; TUBERCULOSTATIC AGENT;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RESISTANT TUBERCULOSIS; FIRST PASS EFFECT; HUMAN; HYDROPHILICITY; LIPID COMPOSITION; MEDICATION COMPLIANCE; MICELLIZATION; MICROEMULSION; NANOEMULSION; NANOFABRICATION; NANOSUSPENSION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PATHOGENESIS; POLYMERIZATION; PRIORITY JOURNAL; SURFACE CHARGE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NANOTECHNOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84938650749     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150531163254     Document Type: Article

References (152)

1. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst 2014; 31: 49-88.
2. Kaur M, Malik B, Garg T, Rath G, Goyal AK. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv 2015; 22(3): 328-34.
3. Kaur R, Garg T, Das Gupta U, Gupta P, Rath G, Goyal AK. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif Cells Nanomed Biotechnol 2014; Epub ahead of print
4. Kaur R, Garg T, Rath G, Goyal AK. Advanced aerosol delivery devices for potential cure of acute and chronic diseases. Crit Rev Ther Drug Carrier Syst 2014; 31: 495-530.
5. Kaur R, Garg T, Malik B, et al. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv 2014; Epub ahead of print
6. Pabreja S, Garg T, Rath G, Goyal AK. Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes Artif Cells Nanomed Biotechnol 2014; Epub ahead of print
7. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst 2012; 29: 1-63.
8. Kaur M, Garg T, Narang RK. A review of emerging trends in the treatment of tuberculosis. Artif Cells Nanomed Biotechnol 2014; Epub ahead of print
9. Buchwald UK, Adetifa IM, Bottomley C, et al. Broad adaptive immune responses to M. tuberculosis antigens precede TST conversion in tuberculosis exposed household contacts in a TBendemic setting. PLoS One 2014; 9: e116268.
10. Hao LH, Guo SC, Liu CC, et al. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and singledrug formulations. Int J Tuberc Lung Dis 2014; 18: 1505-12.
11. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2004; 276: 41-9.
12. Almeida DV, Tyagi S, Li S, et al. Revisiting anti-tuberculosis activity of pyrazinamide in mice. Mycobact Dis 2014; 4: 145.
13. Verissimo LM, Cabral AM, Veiga FJ, et al. Transport properties in aqueous ethambutol dihydrochloride. Int J Pharm 2015; 479(2): 306-11.
14. Jamali H, Paydar M, Radmehr B, Ismail S. Prevalence, characterization, and antimicrobial resistance of Yersinia species and Yersinia enterocolitica isolated from raw milk in farm bulk tanks. J Dairy Sci 2015; 98(2): 798-803.
15. Esfahanizadeh M, Omidi K, Kauffman J, et al. Synthesis and evaluation of new fluorinated anti-tubercular compounds. Iran J Pharm Res 2014; 13: 115-26.
16. Hettenhausen C, Heinrich M, Baldwin IT, Wu J. Fatty acid-amino acid conjugates are essential for systemic activation of salicylic acid-induced protein kinase and accumulation of jasmonic acid in Nicotiana attenuata. BMC Plant Biol 2014; 14: 326.
17. Garg T, Goyal AK. Biomaterial-based scaffolds--current status and future directions. Expert Opin Drug Deliv 2014; 11: 767-89.
18. Garg T, Rath G, Goyal AK. Biomaterials-based nanofiber scaffold: targeted and controlled carrier for cell and drug delivery. J Drug Target 2014: 1-20.
19. Goyal AK, Rath G, Garg T. Nanotechnological approaches for genetic immunization. DNA and RNA nanobiotechnologies in medicine. Diag Treat Dis 2013; 67-120.
20. Singh B, Garg T, Goyal AK, Rath G. Recent advancements in the cardiovascular drug carriers. Artif Cells Nanomed Biotechnol 2014; Epub ahead of print.
21. Sharma R, Singh H, Joshi M, Sharma A, Garg T, Goyal AK, Rath G. Recent advances in polymeric electrospun nanofibers for drug delivery. Crit Rev Ther Drug Carrier Syst 2014; 31: 187-217.
22. Sharma R, Garg T, Goyal AK, Rath G. Development, optimization and evaluation of polymeric electrospun nanofiber: a tool for local delivery of fluconazole for management of vaginal candidiasis. Artif Cells Nanomed Biotechnol 2014; Epub ahead of print.
23. Sharma A, Garg T, Aman A, et al. Nanogel-an advanced drug delivery tool: current and future. Artif Cells Nanomed Biotechnol 2014; Epub ahead of print.
24. Rohilla R, Garg T, Goyal AK, Rath G. Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance. Drug Deliv 2014; Epub ahead of print.
25. Rohilla R, Garg T, Bariwal J, Goyal AK, Rath G. Development, optimization and characterization of glycyrrhetinic acid-chitosan nanoparticles of atorvastatin for liver targeting. Drug Deliv 2014;
26. Epub ahead of print.
27. Singh O, Garg T, Rath G, Goyal AK. Microbicides for the treatment of sexually transmitted hiv infections. J Pharm 2014; Epub ahead of print.
28. Singh H, Sharma R, Joshi M, Garg T, Goyal AK, Rath G. Transmucosal delivery of Docetaxel by mucoadhesive polymeric nanofibers Artif Cells Nanomed Biotechnol 2014; Epub ahead of print.
29. Morie A, Garg T, Goyal AK, Rath G. Nanofibers as novel drug carrier - An overview. Artif Cells Nanomed Biotechnol 2014; Epub ahead of print.
30. Modgill V, Garg T, Goyal AK, Rath G. Transmucosal delivery of linagliptin for the treatment of type- 2 diabetes mellitus by ultrathin nanofibers. Curr Drug Deliv 2014; Epub ahead of print.
31. Modgill V, Garg T, Goyal AK, Rath G. Permeability study of ciprofloxacin from ultra-thin nanofibrous film through various mucosal membranes. Artif Cells Nanomed Biotechnol 2014; Epub ahead of print.
32. Marwah H, Garg T, Goyal AK, Rath G. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv 2014; Epub ahead of print.
33. Malik R, Garg T, Goyal AK, Rath G. Polymeric nanofibers: targeted gastro-retentive drug delivery systems. J Drug Target 2014: 1-16.
34. Kaur V, Garg T, Rath G, Goyal AK. Therapeutic potential of nanocarrier for overcoming to P-glycoprotein. J Drug Target 2014; Epub ahead of print.
35. Kaur P, Garg T, Vaidya B, Prakash A, Rath G, Goyal AK. Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: behavioral and biochemical assessment. J Drug Target 2014; Epub ahead of print.
36. Kaur P, Garg T, Rath G, Murthy RS, Goyal AK. Surfactant-based drug delivery systems for treating drug-resistant lung cancer. Drug Deliv 2014; Epub ahead of print.
37. Kaur N, Garg T, Goyal AK, Rath G. Formulation, optimization and evaluation of curcumin-beta-cyclodextrin-loaded sponge for effective drug delivery in thermal burns chemotherapy. Drug Deliv 2014; Epub ahead of print.
38. Kataria K, Sharma A, Garg T, Goyal AK, Rath G. Novel technology to improve drug loading in polymeric nanofibers. Drug Deliv Lett 2014; 4: 79-86.
39. Patil SS, Mohite ST, Kulkarni SA, Udgaonkar US. Resazurin tube method: rapid, simple, and inexpensive method for detection of drug resistance in the clinical isolates of mycobacterium tuberculosis J Glob Infect Dis 2014; 6: 151-6.
40. Singh N, Sidiq Z, Bhalla M, Myneedu VP, Sarin R. Multi-drug resistant tuberculosis among category I treatment failures--a retrospective study. Indian J Tuberc 2014; 61: 148-51.
41. Outhred AC, Jelfs P, Suliman B, et al. Added value of wholegenome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother 2015; 70(4): 1198-202.
42. Huang Z, Qin C, Du J, et al. Evaluation of the microscopic observation drug susceptibility assay for the rapid detection of MDR-TB and XDR-TB in China: a prospective multicentre study. J Antimicrob Chemother 2015; 70(2): 456-62.
43. Huang Z, Xiong G, Luo Q, et al. Evaluation of the performance of the microscopic observation drug susceptibility assay for diagnosis of extrapulmonary tuberculosis in China: a preliminary study Respirology 2014; 19: 132-7.
44. He L, Wang X, Cui P, et al. ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2015; 95(2): 149-54.
45. Dang TM, Nguyen TN, Wolbers M, et al. Evaluation of microscopic observation drug susceptibility assay for diagnosis of multidrug-resistant tuberculosis in Viet Nam. BMC Infect Dis 2012; 12: 49.
46. Kalia V, Garg T, Rath G, Goyal AK. Development and evaluation of a sublingual film of the antiemetic granisetron hydrochloride Artif Cells Nanomed Biotechnol 2014; Epub ahead of print.
47. Joshi D, Garg T, Goyal AK, Rath G. Development and Characterization of Novel Medicated Nanofibers against Periodontitis. Curr Drug Deliv 2014; Epub ahead of print.
48. Joshi D, Garg T, Goyal AK, Rath G. Advanced drug delivery approaches against periodontitis. Drug Deliv 2014; Epub ahead of print.
49. Johal HS, Garg T, Rath G, Goyal AK. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv 2014; Epub ahead of print.
50. Hussain T, Garg T, Goyal AK, Rath G. Biomedical applications of nanofiber scaffolds in tissue engineering. J Biomater Tissue Eng 2014; 4: 600-23.
51. Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for treating glaucoma. Crit Rev Ther Drug Carrier Syst 2014; 31: 365-405.
52. Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst 2014; 31: 89-119.
53. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv 2013; Epub ahead of print.
54. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst 2013; 30: 369-409.
55. Garg T. An evolutionary approaches in development of needle free injection technologies. Int J Pharm Pharm Sci 2012; 4: 590-6.
56. Garg T, Goyal AK. Liposomes: targeted and controlled delivery system. Drug Deliv Lett 2014; 4: 62-71.
57. Silva AC, Gonzalez-Mira E, Lobo JM, Amaral MH. Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia. Curr Pharm Des 2013; 19: 7185-95.
58. Serpe L, Canaparo R, Foglietta F, Zara GP. Innovative formulations for the controlled and site-specific delivery of antiinflammatory drugs. Curr Pharm Des 2013; 19: 7219-36.
59. Puri A. Phototriggerable liposomes: current research and future perspectives. Pharmaceutics 2013; 6: 1-25.
60. de Paula E, Cereda CM, Fraceto LF, et al. Micro and nanosystems for delivering local anesthetics. Expert Opin Drug Deliv 2012; 9: 1505-24.
61. Pandey R, Sharma S, Khuller GK. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs. Indian J Exp Biol 2004; 42: 562-6.
62. Derrick SC, Dao D, Yang A, Kolibab K, Jacobs WR, Morris SL Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis. PLoS One 2012; 7: e32959.
63. Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1997; 1334: 161-72.
64. Vicario de la Torre M,Benitez-Del-Castillo JM,Vico E, et al Design and characterization of an ocular topical liposomal preparation to replenish the lipids of the tear film. Invest Ophthalmol Vis Sci 2014; 55: 7839-47.
65. Martin C, Low WL, Gupta A, et al. Strategies for antimicrobial drug delivery to biofilm. Curr Pharm Des 2014; 21: 43-66.
66. Rocha S. Targeted drug delivery across the blood brain barrier in Alzheimer's disease. Curr Pharm Des 2013; 19: 6635-46.
67. El-Ridy MS, Yehia SA, Kassem MA, Mostafa DM, Nasr EA, Asfour MH. Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety. Drug Deliv 2015; 22: 21-36.
68. Raza K, Singh B, Singal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B Biointerfaces 2013; 105: 67-74.
69. Khalil NM, de Mattos AC, Carraro TC, Ludwig DB, Mainardes RM. Nanotechnological strategies for the treatment of neglected diseases. Curr Pharm Des 2013; 19: 7316-29.
70. Liu J, Chen S, Lv L, Song L, Guo S, Huang S. Recent progress in studying curcumin and its nano-preparations for cancer therapy Curr Pharm Des 2013; 19: 1974-93.
71. Pandey R, Khuller GK. Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian J Exp Biol 2006; 44: 357-66.
72. Sun Y. Supercritical fluid particle design for poorly water-soluble drugs (review). Curr Pharm Des 2014; 20: 349-68
73. Kwok PC, Chan HK. Nanotechnology versus other techniques in improving drug dissolution. Curr Pharm Des 2014; 20: 474-82
74. Shen SC, Ng WK, Chia LS, Dong YC, Tan RB. Applications of mesoporous materials as excipients for innovative drug delivery and formulation. Curr Pharm Des 2013; 19: 6270-89
75. Pourshahab PS, Gilani K, Moazeni E, Eslahi H, Fazeli MR, Jamalifar H. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsul 2011; 28: 605-13
76. Saraogi GK, Sharma B, Joshi B, et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis J Drug Target 2011; 19: 219-27
77. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003; 52: 981-6
78. Maia CS, Mehnert W, Schafer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 2000; 196: 165-7
79. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005; 55: 430-5
80. Kisich KO, Gelperina S, Higgins MP, et al. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int J Pharm 2007; 345: 154-62
81. Reddy ST, van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25: 1159-64
82. Mathaes R, Winter G, Besheer A, Engert J. Non-spherical microand nanoparticles: fabrication, characterization and drug delivery applications. Expert Opin Drug Deliv 2015; 12(3): 481-92
83. Mathaes R, Winter G, Engert J, Besheer A. Application of different analytical methods for the characterization of non-spherical microand nanoparticles. Int J Pharm 2013; 453: 620-9
84. Kumar A, Gernaey KV, De Beer T, Nopens I. Model-based analysis of high shear wet granulation from batch to continuous processes in pharmaceutical production--a critical review. Eur J Pharm Biopharm 2013; 85: 814-32
85. Cejkova J, Stepanek F. Compartmentalized and internally structured particles for drug delivery--a review. Curr Pharm Des 2013; 19: 6298-314
86. Parikh R, Dalwadi S, Aboti P, Patel L. Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis. J Antibiot (Tokyo) 2014; 67: 387-94
87. Parikh R, Patel L, Dalwadi S. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv 2014; 21: 406-11
88. Thomas TP, Joice M, Sumit M, et al. Design and in vitro validation of multivalent dendrimer methotrexates as a folate-targeting anticancer therapeutic. Curr Pharm Des 2013; 19: 6594-605
89. Cleal K, He L, Watson PD, Jones AT. Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles. Curr Pharm Des 2013; 19: 2878-94
90. Tang YH, Huang AY, Chen PY, Chen HT, Kao CL. Metallodendrimers and dendrimer nanocomposites. Curr Pharm Des 2011; 17: 2308-30
91. Jain JP, Ayen WY, Kumar N. Self assembling polymers as polymersomes for drug delivery. Curr Pharm Des 2011; 17: 65-79
92. Manalan VP, Kolavennu P, Prabahar AE. Dendritic nanoparticulated carriers for the delivery of anti tuberculosis bioactives. Int J Biol Pharm Res 2014; 5: 913-20
93. Leung MH, Harada T, Kee TW. Delivery of curcumin and medicinal effects of the copper(II)-curcumin complexes. Curr Pharm Des 2013; 19: 2070-83
94. Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des 2013; 19: 2047-69
95. Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A. Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces 2010; 79: 467-79
96. Moretton MA, Chiappetta DA, Andrade F, et al. Hydrolyzed galactomannan- modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages. J Biomed Nanotechnol 2013; 9: 1076-87
97. Yu M, Ma H, Lei M, Li N, Tan F. In vitro/in vivo characterization of nanoemulsion formulation of metronidazole with improved skin targeting and anti-rosacea properties. Eur J Pharm Biopharm 2014; 88: 92-103
98. Singh B, Singh R, Bandyopadhyay S, Kapil R, Garg B. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol Colloids Surf B Biointerfaces 2013; 101: 465-74
99. Bandyopadhyay S, Katare OP, Singh B. Optimized self nanoemulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloids Surf B Biointerfaces 2012; 100: 50-61
100. Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrugresistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2: 53ra74
101. Nikonenko B, Reddy VM, Bogatcheva E, Protopopova M, Einck L, Nacy CA. Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 587-9
102. Wang Y, Miao X, Sun L, et al. Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs. Curr Pharm Des 2014; 20: 454-73
103. Zhang X, Li LC, Mao S. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies. Curr Pharm Des 2014; 20: 388-407
104. Moribe K, Ueda K, Limwikrant W, Higashi K, Yamamoto K Nano-sized crystalline drug production by milling technology. Curr Pharm Des 2013; 19: 6246-58
105. Orr MT, Fox CB, Baldwin SL, et al. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. Control Release 2013; 172: 190-200
106. Pereira DM, Valentao P, Andrade PB. Nano- and microdelivery systems for marine bioactive lipids. Mar Drugs 2014; 12: 6014-27
107. Fettiplace MR, Lis K, Ripper R, et al. Multi-modal contributions to detoxification of acute pharmacotoxicity by a triglyceride microemulsion J Control Release 2014; 198C: 62-70
108. Mehta SK, Kaur G, Bhasin KK. Analysis of Tween based microemulsion in the presence of TB drug rifampicin. Colloids Surf B Biointerfaces 2007; 60: 95-104
109. Mehta SK, Kaur G, Bhasin KK. Entrapment of multiple anti-Tb drugs in microemulsion system: quantitative analysis, stability, and in vitro release studies. J Pharm Sci 2010; 99: 1896-911
110. Pedersen JS, Oliveira CL, Hubschmann HB, et al. Structure of immune stimulating complex matrices and immune stimulating complexes in suspension determined by small-angle x-ray scattering Biophys J 2012; 102: 2372-80
111. Kweon MN. Recent progress in mucosal immunology and vaccine development. Exp Mol Med 2014; 46: e86
112. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012; 12: 592-605
113. Dua K, Pabreja K, Ramana MV, Lather V. Dissolution behavior of beta-cyclodextrin molecular inclusion complexes of aceclofenac. J Pharm Bioallied Sci 2011; 3: 417-25
114. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers Adv Drug Deliv Rev 2007; 59: 645-66
115. Rao BP, Suresh S, Narendra C. Physicochemical characterization of _-cyclodextrin and hydroxyl ethyl _-cyclodextrin complexes of rifampicin. Ars Pharm 2006; 47: 39-57
116. Vladimirsky MA,Ladigina GA. Antibacterial activity of liposomeentrapped streptomycin in mice infected with Mycobacterium tuberculosis Biomed Pharmacother 1982; 36: 375-7
117. Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1990; 34: 967-70
118. Gursoy A, Kut E, Ozkirimli S. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy. Int J Pharm 2004; 271: 115-23
119. Labana S, Pandey R, Sharma S, Khuller GK. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents 2002; 20: 301-4
120. El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, Abd El-Alim S Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm 2007; 330: 82-8
121. Gaspar MM, Cruz A, Penha AF, et al. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents 2008; 31: 37-45
122. Ricci M, Giovagnoli S, Blasi P, Schoubben A, Perioli L, Rossi C Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation. Int J Pharm 2006; 311: 172-81
123. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004; 269: 37-49
124. Chono S, Tanino T, Seki T, Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008; 127: 50-8
125. Mehta SK, Jindal N, Kaur G. Quantitative investigation, stability and in vitro release studies of anti-TB drugs in Triton niosomes Colloids Surf B Biointerfaces 2011; 87: 173-9
126. Jain CP, Vyas SP. Preparation and characterization of niosomes containing rifampicin for lung targeting. J Microencapsul 1995; 12: 401-7
127. Jain CP, Vyas SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics. Indian J Pharm Sci 2006; 68: 575-578
128. Maretti E, Rossi T, Bondi M, et al. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis. Int J Pharm 2014; 462: 74-82
129. Hari BN, Chitra KP, Bhimavarapu R, Karunakaran P, Muthukrishnan N, Rani BS. Novel technologies: A weapon against tuberculosis Indian J Pharmacol 2010; 42: 338-44
130. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004; 54: 761-6
131. Ahmad Z, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis Int J Antimicrob Agents 2005; 26: 298-303
132. Ahmad Z, Sharma S, Khuller GK. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine 2007; 3: 239-43
133. Chaubey P, Mishra B. Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis Carbohydr Polym 2014; 101: 1101-8
134. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. Gelatin nanocarriers as potential vectors for effective management of tuberculosis Int J Pharm 2010; 385: 143-9
135. Patomchaiviwat V, Paeratakul O, Kulvanich P. Formation of inhalable rifampicin-poly(L-lactide) microparticles by supercritical anti-solvent process. AAPS PharmSciTech 2008; 9: 1119-29
136. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001; 18: 1405-10
137. Dutt M, Khuller GK. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents 2001; 17: 115-22
138. Ul-Ain Q, Sharma S, Khuller GK. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob Agents Chemother 2003; 47: 3005-7
139. Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007; 51: 2830-6
140. Barrow EL, Winchester GA, Staas JK, Quenelle DC, Barrow WW Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother 1998; 42: 2682-9
141. Chen W, Hu S. Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers. Int J Nanomed 2011; 6: 1535-41
142. Raman C, Berkland C, Kim K, Pack DW. Modeling smallmolecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution. J Control Release 2005; 103: 149-58
143. Franzblau SG, DeGroote MA, Cho SH, et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 2012; 92: 453-88
144. Shen W, Wang H, Peng H, Nie L, Chen D, Jiang M. Facile preparation of stabilized polymeric nanotubes using sacrificial yttrium hydroxide nanotubes as template and block copolymer micelles as precursor. Chem Commun (Camb) 2007; 2360-2
145. Rijcken CJ, Hofman JW, van Zeeland F, Hennink WE, van Nostrum CF. Photosensitiser-loaded biodegradable polymeric micelles: preparation, characterisation and in vitro PDT efficacy. J Control Release 2007; 124: 144-53
146. Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target 2006; 14: 546-56
147. Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv 2014; Epub ahead of print
148. Garg T, Kumar A, Rath G, Goyal AK. Gastroretentive drug delivery systems for therapeutic management of peptic ulcer. Crit Rev Ther Drug Carrier Syst 2014; 31: 531-57
149. Garg T, Goyal AK. Iontophoresis: drug delivery system by applying an electrical potential across the skin. Drug Deliv Lett 2012; 2: 270-280
150. Gagandeep, Garg T, Malik B, Rath G, Goyal AK. Development and characterization of nano-fiber patch for the treatment of glaucoma Eur J Pharm Sci 2014; 53: 10-6
151. Chaudhary S, Garg T, Murthy RS, Rath G, Goyal AK. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J Drug Target 2014; 22(10): 871-82
152. Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2003; 47: 1958-62